 |
|
|
| |
Safety and efficacy of 8-weeks
Glecaprevir/Pibrentasvir in persons
with acute hepatitis C in Germany and Austria
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
<
Axel Baumgarten1, Susanne Reuther2, Johannes Hülsenbeck2, Christoph Boesecke3
1Center for Infectiology, Berlin, Germany; 2AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany; 3Department of Medicine I, University of Bonn, Bonn, Germany
|
| |
|
|
|
|
|
